(Q38127786)

29 August 2017

title

Advances in personalized therapy for lung cancer (English)

1 reference

29 August 2017

1 reference

Eric S Kim

1

1 reference

29 August 2017

Kishan J Pandya

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

12 August 2013

1 reference

Expert Opinion on Medical Diagnostics

29 August 2017

published in

1 reference

29 August 2017

volume

7

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

475-485

1 reference

29 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Advances in understanding cancer genomes through second-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

A comprehensive pathway map of epidermal growth factor receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Lung cancer in never smokers--a different disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

The MET receptor tyrosine kinase in invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

MET pathway as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Role of MetMAb (OA-5D5) in c-MET active lung malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

MET signaling: novel targeted inhibition and its clinical development in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Medical treatment of advanced testicular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Cisplatin: mode of cytotoxic action and molecular basis of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Cellular accumulation of the anticancer agent cisplatin: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Tissue platinum concentration and tumor response in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Characterization of a taxol-resistant human small-cell lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Mutational analysis of the beta-tubulin gene in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2013.826645

10.1517/17530059.2013.826645

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference